Medtronic Activa Approvable With Conditions; Data Show Dyskinesia Drop Off
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's Activa Parkinson's control therapy system should be indicated for treatment only of "advanced levadopa (L-dopa) responsive" Parkinson's patients, FDA's Neurological Devices Panel recommended at a March 31 meeting in Rockville, Maryland.